Emergency Use Authorization (eua) - Vaccines

Relevant Publications

Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19.

Issue Release: 2024

Plasma Adsorption with the MTx.100 Column in Critically Ill COVID-19 Patients: A Prospective Study and Propensity Score Analysis.

Issue Release: 2024

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C).

Issue Release: 2024

A path from synthesis to emergency use authorization of molnupiravir as a COVID-19 therapy.

Issue Release: 2024

COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign.

Issue Release: 2024

Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort.

Issue Release: 2024

In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates.

Issue Release: 2024

CIC2022: An Informatics-Driven Strategy for Improving Immunization Healthcare Data Quality using 2D Barcoding and Barcode Scanning Practices.

Issue Release: 2024

COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic.

Issue Release: 2024

Cardiovascular adverse effects of antiviral therapies for COVID-19: Evidence and plausible mechanisms.

Issue Release: 2024

Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-2025.

Issue Release: 2024

Comparison of regulatory approval system for medicines in emergency among Japan, the United States, the United Kingdom, Europe, and China.

Issue Release: 2024

Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID-19 Under the Emergency Use Authorization.

Issue Release: 2024

COVID-19 pediatric vaccine authorization, FDA authority, and individual misperception of risk.

Issue Release: 2024

Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.

Issue Release: 2023

Compassionate Use of Remdesivir in Pregnancy: A Case Series From a COVID-19 Dedicated Center and Review of Literature.

Issue Release: 2023

Examining Black and Hispanic physicians and other healthcare providers\' attitudes toward the COVID-19 vaccine.

Issue Release: 2023

COVID-19 Vaccination Coverage and Demographic Characteristics of Infants and Children Aged 6 Months-4 Years - United States, June 20-December 31, 2022.

Issue Release: 2023

JYNNEOS Vaccination Coverage Among Persons at Risk for Mpox - United States, May 22, 2022-January 31, 2023.

Issue Release: 2023

Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status.

Issue Release: 2023

What are the Benefits of AI and Machine Learning in Vaccine Development?

How Effective is the DTaP Vaccine?

What Role Do Genetic Variability Play in Emerging Infectious Diseases?

What Impact Has UNICEF Had on Global Vaccination?

What is Antiviral Therapy?

What is Malaria?

What Happens After a Report is Submitted?

What Is the Future of Vaccines?

Should Exercise Be Avoided After Vaccination?

What Topics Are Covered in Vaccine Training Programs?

Emergency Use Authorization (eua) - Vaccines

Relevant Publications

Partnered Content Networks

Relevant Topics